Identity
ATN-161 (Ac-PHSCN-NH2) is a fibronectin-derived integrin antagonist pentapeptide.
Phase 1 study: 26 adults with advanced solid tumors.
Peptide library
ATN-161
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The 26-person, uncontrolled phase I study found no objective tumor responses. Stable disease in some participants can reflect tumor history or selection; dose tolerance is not demonstrated anticancer efficacy.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Phase 1 study: 26 adults with advanced solid tumors.
What the sources found
No objective tumor responses were observed. Some participants had prolonged stable disease; an uncontrolled phase 1 study cannot establish efficacy.
Phase 1 study: 26 adults with advanced solid tumors.
Regulatory scope
No jurisdiction-specific marketing authorization has been verified in this snapshot; study publication is not regulatory approval.
What remains unknown
These findings do not establish human efficacy, long-term safety, or equivalence to products sold under this name. This is a focused source snapshot, not an exhaustive clinical review.
How it works
ATN-161 (Ac-PHSCN-NH2) is a fibronectin-derived integrin antagonist pentapeptide.
Read the study-specific findings and limitations in Medical. Mechanistic activity does not establish a treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- The cited evidence does not establish comprehensive human adverse-event rates.
Contraindications
- A complete clinical contraindication profile has not been established in this review.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Findings
No objective tumor responses were observed. Some participants had prolonged stable disease; an uncontrolled phase 1 study cannot establish efficacy.
Phase 1 study: 26 adults with advanced solid tumors.
Dose
Study context only: 0.1–16 mg/kg in sequential cohorts, infused over 10 minutes three times weekly. This was dose escalation, not an established treatment regimen.
Study-supplied ATN-161; intravenous infusion; adults with advanced solid tumors.
Pharmacokinetics
The phase 1 intravenous study reported a 3.2–5.0-hour half-life. This value cannot be assigned to subcutaneous, oral or retail formulations.
Study formulation; intravenous route; phase 1 oncology population.
References
Cianfrocca et al. Phase 1 trial of ATN-161 in patients with solid tumours. British Journal of Cancer. 2006.
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.